Kura Oncology, Inc. (NASDAQ:KURA) Shares Sold by Public Employees Retirement Association of Colorado

Public Employees Retirement Association of Colorado reduced its holdings in shares of Kura Oncology, Inc. (NASDAQ:KURA) by 15.5% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 9,545 shares of the company’s stock after selling 1,750 shares during the quarter. Public Employees Retirement Association of Colorado’s holdings in Kura Oncology were worth $197,000 as of its most recent filing with the SEC.

Other hedge funds have also made changes to their positions in the company. Hsbc Holdings PLC boosted its holdings in shares of Kura Oncology by 13.4% in the 2nd quarter. Hsbc Holdings PLC now owns 18,300 shares of the company’s stock valued at $374,000 after buying an additional 2,167 shares in the last quarter. Sofinnova Investments Inc. boosted its stake in Kura Oncology by 64.4% in the second quarter. Sofinnova Investments Inc. now owns 825,243 shares of the company’s stock valued at $16,992,000 after acquiring an additional 323,303 shares in the last quarter. Candriam S.C.A. boosted its stake in Kura Oncology by 39.2% in the second quarter. Candriam S.C.A. now owns 906,482 shares of the company’s stock valued at $18,664,000 after acquiring an additional 255,065 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Kura Oncology by 34.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 18,060 shares of the company’s stock worth $372,000 after purchasing an additional 4,654 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its position in shares of Kura Oncology by 4.6% during the second quarter. Bank of New York Mellon Corp now owns 255,897 shares of the company’s stock worth $5,269,000 after purchasing an additional 11,212 shares in the last quarter.

Kura Oncology Stock Performance

Shares of KURA opened at $19.52 on Monday. The stock has a market capitalization of $1.49 billion, a P/E ratio of -9.00 and a beta of 0.84. The company has a debt-to-equity ratio of 0.02, a quick ratio of 14.94 and a current ratio of 14.94. Kura Oncology, Inc. has a 1 year low of $7.41 and a 1 year high of $24.17. The company’s fifty day moving average is $20.02 and its two-hundred day moving average is $20.50.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.63) by $0.04. Kura Oncology’s revenue was up .0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.53) EPS. On average, sell-side analysts predict that Kura Oncology, Inc. will post -2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on KURA. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of Kura Oncology in a research note on Monday, August 12th. Stifel Nicolaus cut their target price on shares of Kura Oncology from $28.00 to $26.00 and set a “buy” rating on the stock in a report on Friday, August 9th. Wedbush reiterated an “outperform” rating and set a $37.00 price target on shares of Kura Oncology in a research note on Friday, August 9th. StockNews.com lowered shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Finally, JMP Securities reiterated a “market outperform” rating and set a $32.00 target price on shares of Kura Oncology in a research note on Monday, August 12th. One investment analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $30.60.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.